Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Cox MC, Castiello L, Mattei M, Santodonato L, D'Agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Carlei D, Monque DM, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini SM, Rozera C, Aricò E, Capone I, Belardelli F. Cox MC, et al. Clin Cancer Res. 2019 Sep 1;25(17):5231-5241. doi: 10.1158/1078-0432.CCR-19-0709. Epub 2019 Jun 6. Clin Cancer Res. 2019. PMID: 31171545 Clinical Trial.
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
Torelli GF, Chiaretti S, Peragine N, Barberi W, Santodonato L, D'Agostino G, Abruzzese E, Del Principe MI, Mancino A, Matarazzo M, Bafti MS, Mancini M, Messina M, Castiello L, Guarini A, Foà R. Torelli GF, et al. Am J Hematol. 2022 Jun 1;97(6):E204-E207. doi: 10.1002/ajh.26537. Epub 2022 Mar 22. Am J Hematol. 2022. PMID: 35315128 Free article. Clinical Trial. No abstract available.
A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
Torelli GF, Rozera C, Santodonato L, Peragine N, D'agostino G, Montefiore E, Napolitano MR, Monque DM, Carlei D, Mariglia P, Pauselli S, Gozzer M, Bafti MS, Girelli G, Guarini A, Belardelli F, Foà R. Torelli GF, et al. Blood Transfus. 2015 Jul;13(3):464-71. doi: 10.2450/2015.0231-14. Epub 2015 Jan 30. Blood Transfus. 2015. PMID: 25761309 Free PMC article. Clinical Trial.
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Aricò E, Casorelli I, Sestili P, Montefiore E, Monque D, Carlei D, Napolitano M, Rizza P, Moschella F, Buccione C, Belli R, Proietti E, Pavan A, Marchetti P, Belardelli F, Capone I. Rozera C, et al. J Transl Med. 2015 May 2;13:139. doi: 10.1186/s12967-015-0473-5. J Transl Med. 2015. PMID: 25933939 Free PMC article. Clinical Trial.
Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M. Santodonato L, et al. J Immunol. 2003 May 15;170(10):5195-202. doi: 10.4049/jimmunol.170.10.5195. J Immunol. 2003. PMID: 12734367
409 results